ADARB1 Antibody - middle region (OASG00206)

Catalog No: OASG00206

Size:100 uL

Western Blot (WB) analysis of specific cells using ADAR2 Polyclonal Antibody.

Product Info

• Predicted Species Reactivity: Human, Mouse, Rat
• Product Format: Liquid. PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
• Clonality: Polyclonal
• Isotype: IgG
• Host: Rabbit
• Application: WB, IHC
  Cellular Location: Nucleus. Nucleus, nucleolus. Shuttles between nucleoli and the nucleoplasm.
  Tissue Location: Highly expressed in brain and heart and at lower levels in placenta. Fair expression in lung, liver and kidney. Detected in brain, heart, kidney, lung and liver (at protein level). Isoform 5 is high expressed in hippocampus and colon. Isoform 5 is expressed in pediatric astrocytomas and the protein has a decreased RNA-editing activity. The decrease in RNA editing correlates with the grade of malignancy of the tumors, with the high grade tumors showing lower editing is seen.
• Reconstitution and Storage: Store at -20C. Avoid repeated freeze/thaw cycles.
• Immunogen: Synthesized peptide derived at 450-530 amino acids from the Internal region of human ADAR2.
• Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
• Concentration: 1 mg/ml
• Specificity: ADAR2 Polyclonal Antibody detects endogenous levels of ADAR2 protein.
• Intended Use: For research use only.
• Application Info: WB 1:500~2000
  IHC 1:100~300
  ELISA 1:20000
  

Target Info

• Gene Symbol: ADARB1
• Gene Full Name: adenosine deaminase, RNA-specific, B1
• Alias Symbols: RED1, ADAR2, DRABA2, DRADA2, NEDHYMS
• NCBI Gene Id: 104; 110532; 25367
• Description of Target: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis.
• Uniprot ID: P78563, Q91ZS8, P51400
• Molecular Weight: 80 kDa